Randy Ban - 02 Dec 2022 Form 4 Insider Report for Inspire Medical Systems, Inc. (INSP)

Signature
/s/ Bryan Phillips, as Attorney-in-Fact for Randy Ban
Issuer symbol
INSP
Transactions as of
02 Dec 2022
Net transactions value
-$2,427,551
Form type
4
Filing time
06 Dec 2022, 15:15:49 UTC
Previous filing
15 Feb 2022
Next filing
05 Jan 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSP Common Stock Options Exercise $9,713 +10,333 +3626% $0.9400* 10,618 02 Dec 2022 Direct F1
transaction INSP Common Stock Sale $1,217,520 -5,188 -49% $234.68 5,430 05 Dec 2022 Direct F2, F3
transaction INSP Common Stock Sale $459,757 -1,954 -36% $235.29 3,476 05 Dec 2022 Direct F2, F4
transaction INSP Common Stock Sale $151,923 -642 -18% $236.64 2,834 05 Dec 2022 Direct F2, F5
transaction INSP Common Stock Sale $333,270 -1,400 -49% $238.05 1,434 05 Dec 2022 Direct F2, F6
transaction INSP Common Stock Sale $274,795 -1,149 -80% $239.16 285 05 Dec 2022 Direct F2, F7
holding INSP Common Stock 167 02 Dec 2022 By son
holding INSP Common Stock 166 02 Dec 2022 By daughter

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSP Stock Option (Right to Buy) Options Exercise $0 -5,333 -96% $0.000000 200 02 Dec 2022 Common Stock 5,333 $0.9400 Direct F8
transaction INSP Stock Option (Right to Buy) Options Exercise $0 -5,000 -14% $0.000000 31,090 02 Dec 2022 Common Stock 5,000 $0.9400 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 19 additional shares acquired under the Inspire Medical Systems, Inc. 2018 Employee Stock Purchase Plan since the Reporting Person's ownership report filed on January 6, 2022.
F2 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.11 to $235.05. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.11 to $236.24. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.24 to $237.21. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.60 to $238.54. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $238.66 to $239.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The option is fully vested and exercisable.